GS-6779

N/A

Report date: 2025/07/17 16:56:22

Base Information

Drug NameGS-6779
Drug Alias NameHB-400 programalternating PICV-LCMV vector based vaccine GS-6779 (Hookipa Pharma/Gilead Sciences)alternating two-vector arenavirus-based vaccine (GS-6779 vectors) (Hookipa Pharma/Gilead Sciences)GS-6779HB-400
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Biological material > Viral vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsHepatitis B, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwanNew Zealand
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesHookipa Pharma IncGilead Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesGilead Sciences Inc
Inactive CompaniesN/A
Active IndicationsHepatitis B, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A